Ovelle Bio has filed a notice of an exempt offering of securities to raise $9,200,000.00 in New Funding.

July 23, 2026 Craig Etkin

According to filings with the U.S. Securities and Exchange Commission, Ovelle Bio is raising up to $9,200,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Ovelle Bio
Ovelle is revolutionizing fertility treatment through human in vitro oogenes is producing eggs from somatic cells. Our approach uses directed differentiation of human iPSCs to ovarian cell types (including granulosa cells and meiotic germ cells) by manipulating expression of TFs and RNA-binding proteins. We are the first company to be develop technology to induce meiosis in human iPSCs. By innovating egg production, we aim to make fertility treatments more accessible and affordable. If we are successful, it will mark a paradigm shift in treatments for infertility, and offer a new path to parenthood for millions of people around the world. Come help us build an exciting future all of us want to live in.

To learn more, visit https://ovelle.bio/
LinkedIn: https://www.linkedin.com/company/ovellebio/

Contact:
Travis Potter, Chief Executive Officer
https://www.linkedin.com/in/travis-potter-27b6636/